European SHARE recommendations set a class-based standard for childhood lupus nephritis
Lupus nephritis remains one of the most consequential organ manifestations of childhood-onset systemic lupus erythematosus, affecting roughly half to most affected children and adolescents. Renal inflammation in this setting is not an abstract complication. It is the pathway to chronic damage, hypertension, proteinuria, and potentially irreversible loss of kidney function if recognition and treatment are delayed. The European SHARE initiative translated that clinical urgency into a structured set of diagnostic and management recommendations designed for pediatric practice across Europe.
The guidance was built through an evidence-based process aligned with European League Against Rheumatism standard operating procedures. A European expert committee, with pediatric nephrology representation, used a nominal group technique to generate consensus. The result was 6 recommendations focused on diagnosis and 20 recommendations addressing treatment choice and treatment goals across all histologic classes of lupus nephritis defined by the International Society of Nephrology/Renal Pathology Society 2003 classification system.
A single treatment objective sits at the center of the document: complete renal response. In pediatric lupus nephritis, that target is clinically meaningful because children must live with the long arc of the disease, not just the acute flare. Persistent proteinuria or incomplete suppression of renal inflammation can seed cumulative injury over years, even when systemic symptoms appear controlled.
Biopsy class drives therapy rather than a one-size-fits-all approach
The recommendations divide treatment by renal histology, reflecting the biological heterogeneity of lupus nephritis. Class I disease should mainly be guided by the broader clinical picture rather than aggressive renal-specific immunosuppression. In practice, minimal mesangial involvement rarely justifies the same intensity of treatment used for proliferative disease, so the kidney biopsy must be interpreted alongside systemic activity and other organ involvement.
Class II disease receives a more measured approach. Initial treatment should be low-dose prednisone, with addition of a disease-modifying antirheumatic drug only if proteinuria persists for 3 months or if the child becomes prednisone dependent. That sequence matters because class II disease often sits at the border between observation and escalation. The kidney may show inflammation, but not at a level that immediately warrants the toxic burden of stronger immunosuppression.
The recommendations draw a bright line at proliferative lupus nephritis. For class III and class IV disease, induction therapy should be mycophenolate mofetil or intravenous cyclophosphamide combined with corticosteroids. These regimens target the immune-driven glomerular injury that defines proliferative disease, where rapid treatment is needed to blunt active inflammation before scarring takes hold. The biology here is straightforward: immune complex deposition and downstream inflammatory activation can destroy glomerular structure quickly, so the first treatment phase must be strong enough to suppress that cascade.
Maintenance therapy is not an afterthought in proliferative disease
Once remission is achieved, the document keeps the focus on durability. For class III and class IV lupus nephritis, maintenance therapy should be mycophenolate mofetil or azathioprine for at least 3 years. That duration reflects the reality that pediatric lupus nephritis often relapses when therapy is withdrawn too quickly. Maintenance treatment is designed to preserve the renal response and reduce the chance that early gains are lost to recurrent immune activation.
The recommendation for at least 3 years of maintenance also reflects the clinical burden of repeated flares. Children with lupus nephritis face years of growth, school attendance, family disruption, and medication exposure. Sustained control of renal disease can reduce the cycle of flare, retreatment, and cumulative nephrotoxic injury. The guidance does not pretend that this is easy therapy, only that incomplete treatment leaves the kidney vulnerable.
Pure class V disease follows a different logic. Induction treatment can consist of mycophenolate mofetil with low-dose prednisone, and maintenance should continue with mycophenolate mofetil. Membranous disease in lupus is often dominated by heavy proteinuria rather than the same proliferative lesions seen in class III or IV disease, so the treatment strategy is tailored to that pattern rather than borrowed wholesale from another class.
Diagnostic consistency is the practical value of the SHARE process
The diagnostic recommendations are as important as the treatment recommendations because renal disease in childhood-onset lupus can be silent at first. Proteinuria, hematuria, active urinary sediment, and declining renal function may emerge before families appreciate the seriousness of kidney involvement. Standardizing when and how clinicians evaluate suspected nephritis reduces the risk that renal inflammation will be missed during early disease.
Expert consensus has particular value in pediatric lupus nephritis because the evidence base is thinner than it is in adult disease. Trials in children are difficult to conduct, histologic patterns vary, and long-term renal outcomes unfold over years rather than months. In that setting, uniform recommendations help reduce geographic variation in care, especially when pediatric rheumatologists and nephrologists are not co-located or when local experience with lupus nephritis is limited.
One sentence captures the clinical stakes: delayed treatment can convert active inflammation into irreversible kidney damage. Once scarring becomes established, no amount of immunosuppression restores lost nephron mass.
What the recommendations change at the bedside
For clinicians caring for children with systemic lupus erythematosus, these recommendations offer a clearer sequence of decisions. Biopsy class should guide intensity of therapy. Complete renal response should be the treatment goal. Proliferative disease should not be undertreated, and maintenance should not be stopped prematurely once remission is achieved.
For families, the value lies in consistency. A child with lupus nephritis may move between pediatric rheumatology, nephrology, and general pediatric care, and inconsistent approaches can create confusion around steroids, immunosuppressive choice, and duration of therapy. The SHARE recommendations give those teams a common framework anchored in renal histology and treatment response rather than guesswork.
The document also leaves room for the realities of pediatric practice. Class I disease is not escalated unnecessarily. Class II disease is observed carefully before treatment is intensified. More aggressive regimens are reserved for the classes most likely to scar the kidney. That tiered structure reflects an attempt to match toxicity to disease biology rather than exposing every child to the same immunosuppressive burden.
The guidance does not eliminate the need for individualized care. It does, however, establish a European standard for diagnosis and treatment that is specific to childhood-onset lupus nephritis and grounded in class-based renal pathology. Future work will still need to define how best to optimize long-term renal preservation, minimize steroid exposure, and adapt therapy for children who do not reach complete renal response despite standard induction and maintenance regimens.